Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea Corporis
Efficacy and Safety of Combined Topical Lactoferrin and Luliconazole Therapy Versus Topical Luliconazole Monotherapy in Egyptian Patients With Tinea Corporis: A Double-Blind Randomized Controlled Trial
This clinical trial will compare three cream treatments for tinea corporis, also called ringworm of the body. It will include Egyptian adults aged 18 to 65 years whose skin infection is confirmed by examining a skin scraping under a microscope.
The main questions are:
- Does using lactoferrin cream with luliconazole cream clear the infection better than either cream alone?
- What side effects occur with each treatment?
- Does the infection return after treatment?
Participants will be assigned by chance to one of three groups:
- Lactoferrin 2% cream and luliconazole 1% cream.
- Luliconazole 1% cream and a matching cream without lactoferrin.
- Lactoferrin 2% cream and a matching cream without luliconazole.
The matching creams contain no active study ingredient and help keep treatment assignments hidden. Participants and the researchers assessing their skin will not know which treatment each participant receives.
Participants will apply their assigned creams twice daily for four weeks. They will attend study visits for skin examinations, symptom assessments, and monitoring for side effects. Skin scrapings will be examined to check whether the infection has cleared. Researchers will also assess changes in the size of the affected areas, itching, treatment satisfaction, and whether the infection returns.
研究概览
地位
条件
详细说明
This prospective, randomized, double-blind, parallel-group clinical trial will evaluate the efficacy and safety of topical lactoferrin 2% cream combined with topical luliconazole 1% cream compared with either agent alone in Egyptian adults with tinea corporis.
The study will be conducted at the outpatient clinics of the Department of Dermatology, Venereology and Andrology, Kafrelsheikh University Hospital, Egypt. Diagnosis will be established by clinical examination and confirmed by direct microscopic examination of skin scrapings using a 10% potassium hydroxide preparation. Written informed consent will be obtained before enrollment.
Eligible participants will be randomly assigned in a 1:1:1 ratio to combination therapy, luliconazole monotherapy with a matching lactoferrin vehicle cream, or lactoferrin monotherapy with a matching luliconazole vehicle cream. Participants and outcome assessors will remain unaware of treatment allocation. Active and matching vehicle creams will have identical appearance, consistency, packaging, and labeling.
Participants will apply their assigned creams to the affected areas twice daily for four weeks. In the combination group, lactoferrin cream will be applied before luliconazole cream. The corresponding application sequence will be maintained in the monotherapy groups using the matching vehicle creams. Additional topical or systemic antifungal treatment will not be permitted during the study.
Baseline assessments will include medical and treatment history, disease duration, previous recurrence, lesion number and location, lesion measurements, clinical photography, and assessment of itching. Subsequent assessments will evaluate treatment response, mycological findings, and adverse events.
The primary efficacy outcomes will be clinical cure and mycological cure. Clinical cure will be defined as complete disappearance of erythema, scaling, active lesion borders, and pruritus. Mycological cure will be defined as a negative potassium hydroxide examination.
Secondary assessments will include changes in lesion size, itching severity measured using a 10-cm visual analog scale, categorical clinical improvement, patient satisfaction, and recurrence after treatment. Recurrence will be assessed as clinical and/or mycological reappearance of infection.
Safety monitoring will include burning, erythema, irritation, pruritus, edema, hyperpigmentation, and other adverse events. The severity of adverse events and their relationship to study treatment will be documented.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Noura El seessy, MD, PhD
- 电话号码：+201000117186
- 邮箱：Nora_Elsiesy@med.kfs.edu.eg
学习地点
-
-
-
Kafr ash Shaykh、埃及
- 招聘中
- Kafrelsheikh University Hospital
-
接触：
- Prof. Dr Reda Biomy, MD, PhD
- 邮箱：medical_research@kfs.edu.eg
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female patients aged 18 to 65 years.
- Clinical diagnosis of tinea corporis.
- Confirmation of dermatophytosis by direct microscopic examination using a potassium hydroxide (KOH) preparation.
- Willingness to participate and provide written informed consent.
Exclusion Criteria:
- Known hypersensitivity to lactoferrin, luliconazole, or any component of the study formulations.
- Pregnancy or breastfeeding.
- Use of systemic or topical antifungal therapy within 4 weeks before enrollment.
- Use of systemic or topical corticosteroids within 4 weeks before enrollment.
- Immunocompromised status.
- Current treatment with immunosuppressive therapy.
- Other dermatological conditions that may interfere with clinical assessment.
- Severe systemic diseases that may affect study outcomes.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Lactoferrin Plus Luliconazole
Participants will apply topical lactoferrin 2% cream followed by topical luliconazole 1% cream to the affected areas twice daily for four weeks. |
Topical cream containing lactoferrin 2% w/w, prepared in the Pharmaceutics Laboratory, Faculty of Pharmacy, Kafrelsheikh University. Applied to the affected areas twice daily for four weeks, before luliconazole cream or its matching placebo, according to treatment allocation. Topical cream containing luliconazole 1% w/w. Applied to the affected areas twice daily for four weeks, after lactoferrin cream or its matching placebo, according to treatment allocation. |
|
有源比较器：Luliconazole Monotherapy
Participants will apply a vehicle cream matching the lactoferrin formulation, followed by topical luliconazole 1% cream, to the affected areas twice daily for four weeks. |
Topical cream containing luliconazole 1% w/w. Applied to the affected areas twice daily for four weeks, after lactoferrin cream or its matching placebo, according to treatment allocation. Vehicle cream without lactoferrin, matching the active lactoferrin cream in appearance, consistency, packaging, and labeling. Applied to the affected areas twice daily for four weeks before luliconazole 1% cream. |
|
有源比较器：Lactoferrin Monotherapy
Participants will apply topical lactoferrin 2% cream followed by a vehicle cream matching the luliconazole formulation to the affected areas twice daily for four weeks. |
Topical cream containing lactoferrin 2% w/w, prepared in the Pharmaceutics Laboratory, Faculty of Pharmacy, Kafrelsheikh University. Applied to the affected areas twice daily for four weeks, before luliconazole cream or its matching placebo, according to treatment allocation. Vehicle cream without luliconazole, matching the active luliconazole cream in appearance, consistency, packaging, and labeling. Applied to the affected areas twice daily for four weeks after lactoferrin 2% cream. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Achieving Clinical Cure
大体时间：Week 6 after treatment initiation (2 weeks after treatment completion)
|
Clinical cure is defined as complete disappearance of erythema, scaling, active lesion borders, and pruritus associated with tinea corporis. The percentage of participants meeting all clinical cure criteria will be compared among treatment groups. |
Week 6 after treatment initiation (2 weeks after treatment completion)
|
|
Percentage of Participants Achieving Mycological Cure
大体时间：Week 6 after treatment initiation (2 weeks after treatment completion)
|
Mycological cure is defined as a negative direct microscopic examination of skin scrapings using a 10% potassium hydroxide preparation. The percentage of participants with a negative examination will be compared among treatment groups. |
Week 6 after treatment initiation (2 weeks after treatment completion)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Skin Lesion Area
大体时间：Baseline and Weeks 1, 2, and 4 after treatment initiation
|
Lesion length and width will be measured using a Vernier caliper to assess change in lesion area from baseline. A reduction in lesion area indicates improvement. |
Baseline and Weeks 1, 2, and 4 after treatment initiation
|
|
Change From Baseline in Pruritus Severity on a Visual Analog Scale
大体时间：Baseline and Weeks 1, 2, and 4 after treatment initiation
|
Pruritus severity will be assessed using a 10-cm visual analog scale. Participants will mark the intensity of itching experienced during the preceding 24 hours on a line ranging from 0 (no pruritus) to 10 (worst imaginable pruritus). The distance from the left end to the participant's mark will be recorded in centimeters. A decrease from baseline indicates improvement. |
Baseline and Weeks 1, 2, and 4 after treatment initiation
|
|
Clinical Improvement Category
大体时间：Week 4 after treatment initiation
|
Clinical response will be categorized as marked improvement, improvement, slight improvement, no change, or aggravation. The distribution of participants across these categories will be compared among treatment groups. |
Week 4 after treatment initiation
|
|
Patient Satisfaction With Treatment
大体时间：Week 4 after treatment initiation
|
Participants will rate their satisfaction with treatment as not satisfied, slightly satisfied, or highly satisfied. The distribution of responses will be compared among treatment groups. |
Week 4 after treatment initiation
|
|
Percentage of Participants With Recurrence Following Cure
大体时间：During the 4 weeks after treatment completion, through Week 8 after treatment initiation
|
Percentage of Participants With Recurrence Following Cure |
During the 4 weeks after treatment completion, through Week 8 after treatment initiation
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- KFSIRB200-1275
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.